HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Suns Sets In Hawaii On Sunscreens Containing Octinoxate, Oxybenzone

This article was originally published in The Rose Sheet

You may also be interested in...



Hawaii’s Sunscreen Ingredient Ban Is On The Books; To Industry, An Affront To Science

As in the case of plastic microbeads some four years ago, the personal-care industry finds itself in the position of having to reformulate potentially on a mass scale due to environmental rather than human safety concerns. And once again the legislation was driven in large part by shoddy science, industry says.

Health, Beauty And Wellness News: Revlon CEO, Rodan + Fields Investment

Too Faced fails in appeal of NAD findings; more of same in supplement GMP warnings; vitamin D benefit for in vitro fertilization shown; TropicSport promotes mineral over chemical sunscreens; Rodan + Fields investment by TPG; and Revlon chairman's daughter takes the helm.

Petition Suggests Environmental Laws Compel FDA To Ban Oxybenzone, Octinoxate In Sunscreens

Center for Biological Diversity asks FDA to ban using oxybenzone and octinoxate in sunscreens, citing their potential contribution to coral bleaching and coral death as well as potential impact on human health. If the agency does not opt to ban the ingredients, the center asks it to conduct a thorough environmental impact assessment, a measure it suggests is warranted under the National Environmental Policy Act.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel